Physician profile
Manmeet Singh
NPI 1184924391
$3,916.10
in general payments reported to CMS, 2019-2025
26 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $329 · 2021: $510 · 2022: $483 · 2023: $820 · 2024: $414 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $579.90 | 2020-2025 | Dragonfly Opstar, Cardiomems, Xience Skypoint |
| Boston Scientific Corporation | $450.62 | 2019-2025 | Avvigo Guidance System, Emerge Push, Watchman Flx |
| Merck Sharp & Dohme LLC | $385.58 | 2022-2025 | Verquvo, Capvaxive |
| Amgen INC. | $364.77 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $354.94 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $245.14 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $242.58 | 2023-2025 | Corevalve Evolut R |
| Abiomed | $156.02 | 2023 | Impella |
| Medtronic Vascular, INC. | $128.23 | 2020 | |
| Angiodynamics, INC. | $121.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $100.32 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $91.68 | 2025 | Assure Wcd |
| Biosense Webster, INC. | $91.38 | 2025 | Carto 3 |
| Lexicon Pharmaceuticals, INC. | $91.06 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $84.56 | 2021-2025 | Farxiga |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.66 | 2019-2021 | |
| Cardiva Medical, INC. | $68.32 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Opko Pharmaceuticals, LLC | $62.63 | 2019-2020 | |
| Cardiovascular Systems INC. | $56.50 | 2020 | |
| Esperion Therapeutics, INC. | $50.34 | 2025 | Nexletol |
| Pfizer INC. | $23.95 | 2023 | |
| Novo Nordisk INC | $22.84 | 2025 | |
| Genzyme Corporation | $20.99 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.15 | 2025 | |
| Baxter Healthcare | $18.80 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.